Celgene has announced the formation of a new strategic research collaboration with the biotechnology company Vividion Therapeutics.
The multi-year collaboration will focus on the identification and development of unique small molecules against targets for a range of oncology, inflammatory and neurodegenerative indications.
“Celgene is allying with Vividion Therapeutics on the development of a new range of drug therapies.“
Through this work, the companies are seeking to advance new small molecules that function through the ubiquitin proteasome system, modulating specific protein levels to deliver therapeutic gains.
This will be accomplished by taking advantage of Vividion's platform for identifying ligands and drug candidates against a selected list of high-value difficult-to-drug targets. It will mark the first time that protein-drug interactions have been precisely assessed directly in native biological systems.
Rupert Vessey, president of research and early development at Celgene, said: "This collaboration will provide both companies with the opportunity for a comprehensive, accelerated drug discovery approach to develop first-in-class therapeutics in areas with high potential impact for patients."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical